Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Return on Invested Capital (2020 - 2023)

Historic Return on Invested Capital for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Q2 2023 value amounting to 0.52%.

  • Tarsus Pharmaceuticals' Return on Invested Capital fell 2500.0% to 0.52% in Q2 2023 from the same period last year, while for Jun 2023 it was 0.52%, marking a year-over-year decrease of 2500.0%. This contributed to the annual value of 0.33% for FY2022, which is 2600.0% down from last year.
  • As of Q2 2023, Tarsus Pharmaceuticals' Return on Invested Capital stood at 0.52%, which was down 2500.0% from 0.33% recorded in Q1 2023.
  • Tarsus Pharmaceuticals' 5-year Return on Invested Capital high stood at 0.02% for Q2 2021, and its period low was 0.52% during Q2 2023.
  • For the 4-year period, Tarsus Pharmaceuticals' Return on Invested Capital averaged around 0.23%, with its median value being 0.27% (2022).
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Return on Invested Capital soared by 2900bps in 2021, and later tumbled by -2500bps in 2022.
  • Over the past 4 years, Tarsus Pharmaceuticals' Return on Invested Capital (Quarter) stood at 0.36% in 2020, then soared by 81bps to 0.07% in 2021, then crashed by -309bps to 0.29% in 2022, then plummeted by -79bps to 0.52% in 2023.
  • Its Return on Invested Capital stands at 0.52% for Q2 2023, versus 0.33% for Q1 2023 and 0.29% for Q4 2022.